42.38
+0.85(+2.05%)
Currency In USD
| Previous Close | 41.53 |
| Open | 41.83 |
| Day High | 42.97 |
| Day Low | 41.37 |
| 52-Week High | 48.26 |
| 52-Week Low | 1.87 |
| Volume | 973,157 |
| Average Volume | 3.86M |
| Market Cap | 3.82B |
| PE | -41.55 |
| EPS | -1.02 |
| Moving Average 50 Days | 23.98 |
| Moving Average 200 Days | 9.62 |
| Change | 0.85 |
If you invested $1000 in Terns Pharmaceuticals, Inc. (TERN) since IPO date, it would be worth $2,304.51 as of December 25, 2025 at a share price of $42.38. Whereas If you bought $1000 worth of Terns Pharmaceuticals, Inc. (TERN) shares 3 years ago, it would be worth $4,745.8 as of December 25, 2025 at a share price of $42.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Dec 11, 2025 9:05 PM GMT
FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its previously announced underwritten public offering of
Terns Announces Pricing of Upsized $650 Million Public Offering
GlobeNewswire Inc.
Dec 10, 2025 4:30 AM GMT
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 16,250,000 s
Terns Announces Proposed Public Offering
GlobeNewswire Inc.
Dec 09, 2025 11:12 AM GMT
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has commenced a proposed underwritten public offering of $400 m